{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:14:48Z","timestamp":1783415688534,"version":"3.54.6"},"reference-count":4,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMJ"],"DOI":"10.4274\/mmj.galenos.2026.24805","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:43:32Z","timestamp":1777970612000},"source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-40 and Soluble CD40 Ligand in Multiple Sclerosis: Inflammatory Signals or Clinically Applicable Biomarkers?"],"prefix":"10.4274","author":[{"given":"Okan","family":"SOKMEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4274\/mmj.galenos.2025.48830","article-title":"Serum interleukin-40 and soluble CD40 ligand as complementary biomarkers for disease activity in multiple sclerosis patients","volume":"40","author":"Neamah","year":"2025","unstructured":"1. Neamah MZ, Sharquie IK, Al Gawwam G. Serum interleukin-40 and soluble CD40 ligand as complementary biomarkers for disease activity in multiple sclerosis patients. Medeni Med J. 2025;40:226-34.","journal-title":"Medeni Med J"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12865-025-00735-2","article-title":"Clinical applications and diagnostic research of GFAP and NfL in MS and NMOSD: a meta-analysis","volume":"26","author":"Lin","year":"2025","unstructured":"2. Lin X, Tong J, Wu W, Pan X. Clinical applications and diagnostic research of GFAP and NfL in MS and NMOSD: a meta-analysis. BMC Immunol. 2025;26:55.","journal-title":"BMC Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3389\/fimmu.2017.01791","article-title":"The CD40-CD40L dy-ad in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"8","author":"SABM","year":"2017","unstructured":"3. Aarts SABM, Seijkens TTP, van Dorst KJF, Dijkstra CD, Kooij G, Lutgens E. The CD40-CD40L dy-ad in experimental autoimmune encephalomyelitis and multiple sclerosis. Front Immunol. 2017;8:1791.","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","unstructured":"4. Vermersch P, Granziera C, Mao-Draayer Y, et al. Inhibition of CD40L with frexalimab in multiple sclerosis. N Engl J Med. 2024;390:589-600.","journal-title":"N Engl J Med"}],"container-title":["Medeniyet Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:32:11Z","timestamp":1783413131000},"score":1,"resource":{"primary":{"URL":"https:\/\/medeniyetmedicaljournal.org\/articles\/interleukin-40-and-soluble-cd40-ligand-in-multiple-sclerosis-inflammatory-signals-or-clinically-applicable-biomarkers\/doi\/MMJ.galenos.2026.24805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":4,"URL":"https:\/\/doi.org\/10.4274\/mmj.galenos.2026.24805","relation":{},"ISSN":["2149-2042"],"issn-type":[{"value":"2149-2042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}